{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:18:28Z","timestamp":1777897108644,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K07910"],"award-info":[{"award-number":["19K07910"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.resinv.2026.101383","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:37:50Z","timestamp":1770698270000},"page":"101383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors"],"prefix":"10.1016","volume":"64","author":[{"given":"Tatsuya","family":"Hirano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-0598","authenticated-orcid":false,"given":"Ichidai","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-3349","authenticated-orcid":false,"given":"Masahiro","family":"Morise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kennosuke","family":"Karube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-1574","authenticated-orcid":false,"given":"Takayasu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-576X","authenticated-orcid":false,"given":"Koji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0207-9483","authenticated-orcid":false,"given":"Yuichiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-9576","authenticated-orcid":false,"given":"Mitsuo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-3329","authenticated-orcid":false,"given":"Tomoki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101383_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.resinv.2026.101383_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ijms23010245","article-title":"Current immunotherapeutic strategies targeting the PD-1\/PD-L1 axis in non-small cell lung cancer with oncogenic driver mutations","volume":"23","author":"Tanaka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2026.101383_bib3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101383_bib4","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101383_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101383_bib6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib7","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101383_bib8","article-title":"Thoracic tumours WHO classification of tumours","volume":"vol. 5","year":"2021"},{"key":"10.1016\/j.resinv.2026.101383_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.5858\/arpa.2012-0263-RA","article-title":"Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 international association for the study of lung cancer\/american thoracic society\/European respiratory society classification","volume":"137","author":"Travis","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.resinv.2026.101383_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043820","article-title":"Observational cross-sectional study of 5279 bronchoscopy results for the practical effectiveness of various biopsy techniques in the diagnosis of lung diseases with particular emphasis on lung cancer","volume":"11","author":"B\u0142ach","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.resinv.2026.101383_bib11","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/JTO.0b013e318227142d","article-title":"Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens","volume":"6","author":"Sigel","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3892\/ol.2014.2302","article-title":"Clinical significance of the 'not otherwise specified' subtype in candidates for resectable non-small cell lung cancer","volume":"8","author":"Tane","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.resinv.2026.101383_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/JTO.0000000000000271","article-title":"Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome","volume":"9","author":"Righi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00432-019-03012-z","article-title":"Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified","volume":"145","author":"Ota","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2022.08.007","article-title":"Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment","volume":"172","author":"Akhave","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib16","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.21037\/jtd-21-388","article-title":"PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis","volume":"13","author":"Shen","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2026.101383_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12885-022-09741-8","article-title":"Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis","volume":"22","author":"Gen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cllc.2020.01.011","article-title":"Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation","volume":"21","author":"Tanaka","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.resinv.2026.101383_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.resinv.2026.101383_bib21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/JTO.0b013e318211dd16","volume":"6","author":"Pelosi","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cllc.2015.03.008","article-title":"Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer","volume":"16","author":"Kitazono","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12885-019-5773-3","article-title":"A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer","volume":"19","author":"Tsunoda","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000369860","article-title":"Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens","volume":"89","author":"Oki","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2026.101383_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2020.03.029","article-title":"Outstanding clinical efficacy of PD-1\/PD-L1 inhibitors for pulmonary pleomorphic carcinoma","volume":"132","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Velcheti","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jnci\/djab183","article-title":"SRGN-triggered aggressive and immunosuppressive phenotype in a subset of TTF-1-Negative lung adenocarcinomas","volume":"114","author":"Tanaka","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.resinv.2026.101383_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.21037\/tlcr-24-127","article-title":"Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review","volume":"13","author":"Wei","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.resinv.2026.101383_bib29","article-title":"Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101383_bib30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cllc.2023.06.002","article-title":"Association of molecular profiles and mutational status with distinct histological lung adenocarcinoma subtypes. An analysis of the LACE-Bio\/Data","volume":"24","author":"Ashok Kumar","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101383_bib31","article-title":"Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer","volume":"4","author":"Ferrara","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2026.101383_bib32","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00432-022-04286-6","article-title":"PD-1\/PD-L1 inhibitors in treatment-na\u00efve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials","volume":"149","author":"Wankhede","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101383_bib33","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101383_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:47:35Z","timestamp":1777625255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2212534526000171"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101383","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}],"article-number":"101383"}}